Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset.
Cho BC, Hayashi H, Lee JS, Lee SH, Danchaivijitr P, Cheng Y, Liu B, Alip A, Xiong H, How SH, Chang GC, Yang JC, Yoshioka H, Nahit Şendur MA, Prabhash K, Azuma K, Lee YG, Lin CC, Matsumoto S, Sunpaweravong P, Xia Y, Martinez M, Bauml JM, Sethi S, Lu S.
Cho BC, et al. Among authors: lee sh, lee js, lee yg.
Lung Cancer. 2025 Jun;204:108496. doi: 10.1016/j.lungcan.2025.108496. Epub 2025 Mar 15.
Lung Cancer. 2025.
PMID: 40300278
Free article.
Clinical Trial.